Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME

被引：0

作者：

Inzucchi, S. E. ^{[1
]}

Khunti, K. ^{[2
]}

Fitchett, D. H. ^{[3
]}

Wanner, C. ^{[4
]}

Mattheus, M. ^{[5
]}

George, J. T. ^{[6
]}

Ofstad, A. P. ^{[7
]}

Zinman, B. ^{[8
]}

机构：

[1] Yale Sch Med, Sect Endocrinol, New Haven, CT USA

[2] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England

[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[4] Wurzburg Univ Clin, Div Nephrol, Wurzburg, Germany

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Boehringer Ingelheim Norway KS, Asker, Norway

[8] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷

关键词：

Sodium glucose co-transport inhibitor 2; Cardioprotection; Heart failure;

D O I：

10.1016/j.metabol.2019.12.071

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：1

共 50 条

[1] Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
Inzucchi, Silvio E.
Khunti, Kamlesh
Fitchett, David H.
Wanner, Christoph
Mattheus, Michaela
George, Jyothis
Ofstad, Anne Pernille
Zinman, Bernard
DIABETES, 2019, 68
[2] Consistent cardiovascular (CV) benefits from empagliflozin across the spectrum of CV risk factor control: post hoc analysis from EMPA-REG OUTCOME
Inzucchi, S. E.
Khunti, K.
Fitchett, D. H.
Wanner, C.
Mattheus, M.
George, J. T.
Ofstad, A.
Zinman, B.
DIABETOLOGIA, 2019, 62 : S328 - S328
[3] Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
Inzucchi, Silvio E.
Khunti, Kamlesh
Fitchett, David H.
Wanner, Christoph
Mattheus, Michaela
George, Jyothis T.
Ofstad, Anne Pernille
Zinman, Bernard
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : 3025 - 3035
[4] EMPA-REG OUTCOME: consistent reduction in risk of cardiovascular (CV) outcomes and mortality with empagliflozin (EMPA) irrespective of sulphonylurea (SU) use at baseline
George, J. T.
Inzucchi, S. E.
Fitchett, D.
Mattheus, M.
Janista, C.
Zinman, B.
DIABETOLOGIA, 2017, 60 : S425 - S426
[5] Empagliflozin Improves Cardiovascular (CV) Outcomes Regardless of Improvement in Cardiac and Vascular Hemodynamic Markers in Type 2 Diabetes Patients at High CV Risk in EMPA-REG OUTCOME
Chilton, Robert J.
Gullestad, Lars
Park, Sung-Ha
Fitchett, David
Silvio, E.
Hehnke, Uwe
Woerle, Hans Juergen
Johansen, Odd Erik
CIRCULATION, 2017, 136
[6] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
Odutayo, Ayodele
Zinman, Bernard
Wanner, Christoph
Zwiener, Isabella
Lund, Soren S.
Hantel, Stefan
Fitchett, David
Udell, Jacob A.
CJC OPEN, 2024, 6 (07) : 868 - 875
[7] Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME
Jurisic-Erzen, D.
Johansen, O.
George, J.
Mattheus, M.
Zinman, B.
Inzucchi, S.
DIABETOLOGIA, 2016, 59 : S349 - S349
[8] EMPA-REG OUTCOME: Consistent reduction in risk of cardiovascular outcomes and mortality with empagliflozin irrespective of sulphonylurea use at baseline
Inzucchi, S. E.
George, J. T.
Fitchett, D.
Mattheus, M.
Janista, C.
Zinman, B.
DIABETIC MEDICINE, 2018, 35 : 96 - 96
[9] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis
Ferrannini, Ele
Mark, Michael
Mayoux, Eric
DIABETES CARE, 2016, 39 (07) : 1108 - 1114
[10] Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
Fisher, Miles
BRITISH JOURNAL OF DIABETES, 2020, 20 (02): : 138 - 141

← 1 2 3 4 5 →